News
The Chopra Foundation launches campaign against female genital mutilation
More than 200 million girls and women alive today have undergone FGM in 30 countries in Africa, Asia and the Middle East
The Chopra Foundation and the Never Alone Initiative alongside the tech-based social impact start-up Seva.Love and the African organisation The Girl Generation have launched a campaign against female genital mutilation.
The Chopra Foundation, a US NPO conducting scientific research on health and wellbeing, has announced the partnership in an effort to put an end to Female Genital Mutilation/Cutting (FGM/C) and empower survivors and women at-risk with the education, tools and resources they need to navigate the societal, emotional, spiritual and physical complexities of this issue.
The Chopra Foundation, Never Alone and Seva.Love will be deploying an awareness and fundraising campaign over the next year intended to ignite a global dialogue around this issue, while raising the funds needed to tackle it by rallying the web3 community.
FGM/C, a practice that refers to the partial or total removal of external female genitalia or other injury to the female genital organs for non-medical reasons, is often performed without anaesthesia or proper aftercare and has no benefits for girls or women.
According to the World Health Organisation (WHO), it is estimated that more than 200 million girls and women alive today have undergone FGM in 30 countries in Africa, the Middle East and Asia, and that seven girls are cut every minute.
Mostly carried out on young girls between infancy and age 15, the practice is a violation of the human rights of girls and women, says WHO.
Dr Leyla Hussein, global advocacy director and deputy team leader for The Girl Generation and FGM survivor, said: “This partnership is extremely critical as it demonstrates that we will show up for African girls.
“FGM is violence and leaves long-life physical and emotional scars. We are ready for a global movement that will end FGM.”
Despite the frequency of the practice, FGM/C continues to live in the shadows and receives little representation at global level, Hussein says.
The collaboration is hoped to dismantle the structures that enable FGM/C to exist and provide survivors and those at risk with the tools and resources needed to live safe, healthy lives.
“FGM is a relic of barbaric times,” said Dr Deepak Chopra, founder of the foundation.
“There should be no tolerance for this procedure, and it needs to be a criminal offence wherever it continues to be practiced.
“The Chopra Foundation is committed to raising awareness around this brutal custom and eliminating it for all of time.”
Poonacha Machaiah, CEO of the Chopra Foundation and Seva.Love, said: “We must make every effort to eradicate this inhumane practice.
“Millions have already been traumatised by FGM and this practice must end.”
Humanitarian and Never Alone Initiative co-founder, Gabriella Wright, said: “We owe it to our future generations to take care of each other now.
“Let’s break this cycle of trauma for a global collective healing that can sustain humanity and the planet. Everyone matters in this journey.”
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Wellness4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur5 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health






